Joseph S Dillon
Overview
Explore the profile of Joseph S Dillon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
884
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shilyansky J, Chan C, Xiao S, Gribovskaja-Rupp I, Quelle D, Howe J, et al.
Surgery
. 2024 Dec;
179:108943.
PMID: 39665969
Objectives: Semaglutide is a glucagon-like peptide 1 (GLP-1) analog that binds to GLP-1 receptors (GLP-1R) on beta-cells and neuronal cells and is used for treating type 2 diabetes and obesity....
2.
Howe J, Sherman S, Dillon J
Ann Surg Oncol
. 2024 Dec;
32(2):1187-1188.
PMID: 39645558
No abstract available.
3.
Gadens Zamboni C, Dundar A, Jain S, Kruzer M, Loeffler B, Graves S, et al.
EJNMMI Rep
. 2024 Nov;
8(1):39.
PMID: 39613925
Background: Indices of tumor heterogeneity on somatostatin receptor PET/CT scans may potentially serve as predictive biomarkers of treatment efficacy in neuroendocrine tumor (NET) patients undergoing [Lu]Lu-DOTA-TATE PRRT. Methods: NET patients...
4.
Borbon L, Sherman S, Breheny P, Chandrasekharan C, Menda Y, Bushnell D, et al.
Ann Surg Oncol
. 2024 Nov;
32(2):1193-1194.
PMID: 39578324
No abstract available.
5.
Borbon L, Sherman S, Breheny P, Chandrasekharan C, Menda Y, Bushnell D, et al.
Ann Surg Oncol
. 2024 Nov;
32(2):1136-1148.
PMID: 39505730
Background: Peptide receptor radionuclide therapy (PRRT) is an effective treatment for advanced gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). We investigated a 2-decade experience with PRRT to determine whether PRRT confers a...
6.
Xu T, Dillon J, Maluccio M, Quelle D, Nash S, Cho H, et al.
J Cancer Res Clin Oncol
. 2024 Nov;
150(11):485.
PMID: 39488644
Purpose: Renal and hematological toxicity are side effects and dose-limiting factors of Peptide Receptor Radionuclide Therapy (PRRT). We aimed to assess the changes in renal and hematological function and associations...
7.
Howe J, Menda Y, Chandrasekharan C, Bellizzi A, Quelle D, ODorisio M, et al.
Endocr Pract
. 2024 Sep;
31(1):4-18.
PMID: 39349242
The Iowa Neuroendocrine Tumor (NET) Clinic was founded and developed by two remarkable physicians, Thomas and Sue O'Dorisio. Tom was an Endocrinologist and close friend and colleague of Aaron Vinik....
8.
Wahba A, Tan Z, Dillon J
Curr Probl Cancer
. 2024 Aug;
52:101130.
PMID: 39213785
Functional neuroendocrine neoplasms (NENs) are those associated with specific symptoms related to the hormonal secretion of the NENs. Although less than 25 % of NENs are functional at diagnosis, the...
9.
Mouser B, Howe J, Atari O, Dillon J, Chandrasekharan C, Parekh K, et al.
Int J Cardiol Cardiovasc Risk Prev
. 2024 Jun;
22:200293.
PMID: 38911359
Background: Screening for carcinoid heart disease (CHD), has historically lacked consensus expert guidelines. In 2017, the North American Neuroendocrine Tumor Society (NANETS) released expert recommendations for CHD screening among NET...
10.
Grewal U, Loeffler B, Paschke A, Dillon J, Chandrasekharan C
J Gastrointest Cancer
. 2024 May;
55(3):1165-1170.
PMID: 38780680
Introduction: The available data for the safety and efficacy of repeat peptide receptor radionuclide therapy (PRRT) are almost exclusively from European centers. We present an updated experience with repeat PRRT...